常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.93/-0.97
|
|
企业价值
26.46M
|
| 资产负债 |
|
每股账面净值
1.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
636.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/19 12:33 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. |

0.61955 
